Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Management of Epstein-Barr Virus Positive Splenomegaly with Areas of Infarction

Diagnosis and Assessment

  • CT scan with intravenous contrast is the gold standard for diagnosing splenic infarction, with sensitivity and specificity of 90-95%, showing peripheral low-density, wedge-shaped areas 1
  • MRI offers similar diagnostic accuracy to CT for splenic infarction, while ultrasonography is less sensitive 1
  • EBV infection should be confirmed through serological testing (EBV IgM, IgG) and/or PCR testing of blood samples 2
  • Monitor for signs of complications including persistent fever, recurrent bacteremia, or other signs of sepsis which may indicate progression to splenic abscess 1

Initial Management

  • Monitor EBV viral load by quantitative PCR to assess disease activity and response to treatment 2

Monitoring for Complications

  • Regular clinical assessment for signs of splenic rupture or hemorrhage, which is a rare but serious complication 1
  • Serial imaging (ultrasound or CT) to monitor the evolution of splenic infarcts and splenomegaly 1
  • Watch for development of pseudocyst formation as a potential complication 1
  • Monitor for signs of secondary bacterial infection or abscess formation 1

Indications for Surgical Intervention

  • Splenectomy is indicated for development of splenic abscess 1
  • Surgical intervention is necessary for splenic rupture with hemorrhagic shock or failed non-operative management with continued hemodynamic instability 1, 3
  • Consider intervention for persistent symptoms and complications such as hemorrhage, splenic abscesses, or pseudocyst formation 3

Special Considerations

  • In patients with underlying hematological conditions, cytoreductive therapy for the primary disease can lead to successful regression of splenic infarction without surgical intervention 3
  • For patients with post-transplant EBV infections, reduction of immunosuppression should be considered when possible 4
  • In transplant patients with high EBV viral loads, rituximab (375 mg/m²) may be considered as pre-emptive therapy to prevent progression to post-transplant lymphoproliferative disorder (PTLD) 4

Follow-up

  • Continue monitoring until resolution of symptoms and radiographic improvement of splenic lesions 1
  • Differentiation between uncomplicated infarction and abscess can be made based on clinical and radiographic improvement with appropriate therapy 1